Zai Lab's ZL-1503 Shows Promising Preclinical Results for Atopic Diseases
Event summary
- Zai Lab presented preclinical data for ZL-1503, an IL-13/IL-31Rα bispecific antibody, at the IMMUNOLOGY2026 conference on April 18, 2026.
- A single dose of ZL-1503 demonstrated sustained suppression of itch and inflammation over 112 days in non-human primates.
- The study showed significant improvement in lung function, airway inflammation, and symptoms of allergic rhinitis and conjunctivitis.
- Zai Lab initiated Phase 1/1b clinical trials for ZL-1503 in December 2025 in Australia, New Zealand, and China.
The big picture
Zai Lab's ZL-1503 represents a strategic advancement in targeting both inflammatory and pruritogenic pathways simultaneously, addressing a significant unmet need in atopic diseases. The preclinical data supports the potential for faster onset of action and superior efficacy compared to existing treatments. This positions Zai Lab competitively in the immunology space, particularly as it advances into human clinical trials.
What we're watching
- Clinical Progress
- How the Phase 1/1b clinical trials will validate ZL-1503's efficacy and safety in humans.
- Market Positioning
- Whether Zai Lab can establish ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis.
- Regulatory Pathway
- The pace at which regulatory approvals will be sought and obtained in key markets.
Related topics